The FDA on August 14, 2023, granted accelerated approval to ELREXFIO®, a bispecific B-Cell Maturation Antigen (BCMA)-directed CD3 T-cell engager, for adults with Relapsed or Refractory multiple myeloma who have received at least four prior lines of therapy, including a Proteasome Inhibitor, an Immunomodulatory agent, and an anti-CD38 monoclonal antibody. ELREXFIO® is a product of Pfizer, Inc.
Bottom Ad
Advertisement
Subscribe
